ERBC (European Research Biology Center)
Natalia NIEMIR-DEVEAU, PhD, is an accomplished professional with extensive experience in business development and scientific research. Currently serving as Business Development Manager and Discovery Referent at the European Research Biology Center since September 2021, Natalia has a proven track record in managing business initiatives across Germany, Austria, and Poland. Previous roles include Business Development Manager and Scientific Consultant at genOway, where responsibilities involved evaluating genetic strategies for research model development, as well as working as an Innovation Funding Consultant at Sogedev, assisting innovative companies with project financing. Research experience spans multiple prestigious institutions, including the Institut Cochin, King's College London, and Yale University School of Medicine, focusing on genetic therapies and neuropathological analyses. Natalia holds a PhD in Genetics/Biotechnology/Biotherapies from Université Paris Cité and has completed diploma programs in medical sciences and innovation.
This person is not in any offices
ERBC (European Research Biology Center)
Stemming from the merger of two reference CROs in pharmacology and toxicology (CERB and RTC), European Research Biology Center (ERBC) is a European leader in non-clinical studies. It offers to healthcare and chemical professionals a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity. Based in Baugy (France) and Roma (Italy), ERBC provides all services from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, also benefiting from a world class academic and private network. Every year, study reports from our two Centers are successfully used in support of market authorization and new product approval submissions around the world, including the European (EMA, ECHA), US (FDA and EPA) and Japanese (MHLW and MAFF) regulatory authorities. Investment in outstanding scientific and technical manpower, high-tech equipment and facilities are crucial cornerstones of our sound and organic growth. The quality and reliability of our performance is reflected by the many ongoing and long-lasting collaborations we maintain with leading international pharmaceutical and chemical companies. ERBC is deeply engaged in animal ethics and welfare. ERBC supports the Basel Declaration, respects the 3Rs concept and continually improves its tools and procedures to maximize the balance between the benefit for health and the animal well-being.